LOS ANGELES, April 4, 2011 /PRNewswire/ — NeuroSigma, Inc.
(“NeuroSigma”), a Los Angeles-based medical technology company
established to in-license and develop early stage technologies with
the potential to transform medical practice, today announced that
it has retained CCG Investor Relations to design and execute its
strategic communications and investor relations campaign.
“We look forward to working closely with CCG to establish and
enhance our profile in the investment community and with all our
stakeholders,” said Lodwrick M. Cook, Chairman of NeuroSigma.
“Given CCG’s track record of professional experience
representing a wide spectrum of high-growth, U.S. companies, we are
confident that our new partnership will help us achieve those
goals,” added Dr. Leon Ekchian, President and CEO of
Founded by experts in business management and the healthcare
industry, NeuroSigma has a growing pipeline of therapies in
clinical trials targeting epilepsy, depression, post-traumatic
stress disorder (PTSD), and obesity, among others. NeuroSigma
is actively engaged in cutting-edge preclinical research and
development, as well as groundbreaking Phase I and Phase II
clinical trials at the University of California, Los Angeles (UCLA)
and is currently utilizing two distinct therapy platforms:
Trigeminal Nerve Stimulation (TNS) – A proprietary
therapy developed at UCLA and exclusively licensed to
Deep Brain Stimulation (DBS) – NeuroSigma is
supporting the development of new therapies for this platform,
which was originally pioneered in France for the treatment of
essential tremor and Parkinson’s disease.
“We are very pleased to be working with NeuroSigma,” said
William Coffin, Chairman of CCG Investor Relations. “At a
time when translating important medical research from ‘lab bench to
bedside’ has never been more valuable, NeuroSigma is providing that
expertise, working with the ve